LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.…
LifeMD: 3 Key Takeaways for Long-Term Investors
LifeMD (NASDAQ: LFMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 347 employees.
The shares were at 1.445 USD on 20 November 2026, down 72.4% over 52 weeks. Its 52-week range is 1.381 USD to 5.440 USD: the price is 73.4% below the high and 4.6% above the low.
Its market capitalisation is 69.84M USD.
LifeMD reports return on equity of 62.0%, an operating margin of -11.1% and revenue down 6.5% year over year.
It holds more cash than debt, a net cash position of 16.07M USD. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. The next earnings report is expected on 9 March 2027.